Inhibitor

drug discovery

Advances in Research on Small Molecule Janus Kinase (JAK) Inhibitors

Janus kinases (JAKs) belong to the non-receptor tyrosine kinase family, and their JAK-STAT signaling pathway with signal transducers and activators of transcription (STAT) can affect cell proliferation, differentiation, apoptosis, and […]

drug R&D

Small Molecule Targeted Cancer Immunotherapy Draws the New Roadmap for Cancer Treatment

As an alternative to surgery, radiotherapy, and chemotherapy, tumor therapy via the immune pathway has made significant advances in recent years. Among the targeted drugs of immuno-oncology (IO), Ab drugs […]

Covalent and Non-Covalent BTK Inhibitors: Development and Applications

What Is the Potential of BTK Inhibitors?

B Cell Receptor (BCR) signaling pathway overview BCR is a transmembrane protein complex that controls B cell maturation, survival, apoptosis, and the production of plasma cell antibodies starting from the […]

Small Molecule Drugs for Cancer Immunotherapy

Progress and Promise: Small Molecule Drugs for Cancer Immunotherapy

Overview of cancer immunotherapy The most widely studied cancer immunotherapies are PD-1/PD-L1 immune checkpoint inhibitors and chimeric antigen receptor-T cell (CAR-T) therapy. With the expanded clinical applications, some defects of […]

FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer

FDA Approved ALK Inhibitors for ALK-Positive Non-Small Cell Lung Cancer

Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a […]

Cancer

Discovery of BLU-945 Brings Hope to EGFR-Positive NSCLC Patients

Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]

drug

The Latest and Most Complete Collection of Cancer Drugs

1. Respiratory system 1.1. Lung cancer Drug Name Trade name CAS Target Description Approved Status Gefitinib lressa 184475-35-2 EGFR Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both […]

drug

A Brief Discussion on ALK Inhibitors

In 2007, Japanese professors firstly discovered ALK rearrangement and identified the fusion of ALK and EML4 in non-small cell lung cancer specimens. EML4 can promote the activation of ALK kinase […]

Cancer

Summary of Kinase Inhibitors | CDK2 and Its Inhibitors

CDKs belong to the serine/threonine protein kinase family, and their kinase activity requires binding to cyclins. Abnormalities in CDKs have been reported to cause proliferation, genomic and chromosomal instability that […]

drug

Research Progress of Small Molecule Inhibitors Targeting MYC

MYC protein is an inherently disordered protein, which lacks a hydrophobic pocket or groove suitable for binding small molecule compounds. Currently, no small molecule compounds that can bind MYC have […]